ADPKD Guide
Readable, evidence-first ADPKD treatment, symptoms, diet, trials, and research updates for patients, families, and clinicians.
Last sweep: Jun 1, 2026
What’s New Methodology References Support GitHub
Ask ADPKD Patient Guide Treatment Slow Progression Trials Cure
More
What’s New Newly Diagnosed Tolvaptan Lifestyle Diet Symptoms Clinicians Methodology References Support
Tolvaptan Guide Tier 1 — Approved

Tolvaptan — the only approved disease-modifying therapy for ADPKD

It slows progression in appropriate patients. It is not a cure. It requires real monitoring. Here is what the evidence actually says.

Last reviewed: July 23, 2026

How tolvaptan works

Blocks vasopressin at kidney collecting ducts → reduces cAMP → cysts grow more slowly.

Tolvaptan is a vasopressin V2 receptor antagonist. Vasopressin (ADH) normally signals kidney cells to conserve water. In ADPKD, this signaling also drives the cyclic AMP (cAMP) pathway that fuels cyst cell growth and fluid secretion.

By blocking the V2 receptor, tolvaptan lowers cAMP in collecting duct cells. The result: cysts accumulate fluid more slowly, kidney volume grows more slowly, and eGFR declines more slowly in patients who qualify.

The tradeoff: because it blocks water resorption, you produce 3–5 litres of urine per day. You will be thirsty. This is the mechanism — not a side effect to push through without fluids.

Brand names and approval status

  • Jynarque — US FDA approved (2018) for rapidly progressing ADPKD
  • JINARC — EMA approved (EU, 2015)
  • Samsca — older brand, used off-label for ADPKD before dedicated approval

In the US, dispensing requires enrollment in the JYNARQUE REMS program due to liver toxicity risk. Your prescribing centre will manage this.

Who is a candidate?

Tolvaptan is for adults with rapidly progressing ADPKD. "Rapidly progressing" has a specific clinical meaning — not everyone with ADPKD qualifies.

Progression risk criteria

  • Mayo Classification 1C, 1D, or 1E — based on kidney volume adjusted for height and age
  • PROPKD score ≥ 7 — genotype + clinical scoring system
  • eGFR decline ≥ 5 mL/min/1.73m² over 1 year, or ≥ 2.5 mL/min/1.73m² over 5 years

Minimum requirements

  • eGFR ≥ 25 mL/min/1.73m² at initiation (CKD Stage 3a or better)
  • Able to tolerate aquaresis — access to fluids and facilities, no volume-depletion risk
  • No pre-existing significant liver disease

Not appropriate if:

  • eGFR < 25 (benefit uncertain, increased risk)
  • Liver disease or unexplained elevated liver enzymes
  • Inability to access fluids or monitor for dehydration
  • Pregnancy or breastfeeding
  • Drugs that strongly inhibit CYP3A4 (eg. ketoconazole, clarithromycin)

What the trials showed

Two large randomised trials established tolvaptan's evidence base:

TEMPO 3:4 trial Tier 1

N = 1,445 patients, 3 years

  • Kidney volume growth: 49% slower with tolvaptan vs placebo
  • eGFR decline: 26–37% slower
  • Fewer kidney pain events, UTIs, and hypertension episodes
  • Enrolled earlier-stage patients (eGFR ≥ 60 in most)

PMID23121377 — Slowed TKV growth and kidney function decline vs placebo over 3 years

REPRISE trial Tier 1

N = 1,370 patients, 1 year

  • Enrolled patients with already-declining eGFR (eGFR 25–65)
  • eGFR decline: 1.27 mL/min/yr less loss with tolvaptan
  • Confirmed benefit extends to later-stage rapidly progressing patients
  • Liver enzyme elevations occurred in ~5% — trial mandated monitoring

PMID29105594 — Slower eGFR decline than placebo over 1 year

Side effects to expect

Aquaresis is not optional — it is the mechanism. Plan your day around it.
  • Aquaresis (the big one): urinating 3–5 litres/day, constant thirst. This is expected and intentional. You must drink enough to compensate — at least 3–4 litres/day.
  • Nocturia: waking 3–5 times per night is common, especially early on.
  • Dry mouth and fatigue from high fluid turnover.
  • Liver enzyme elevation: occurs in ~5% of patients, usually reversible with dose reduction or stopping. Rarely serious (<0.2%) but requires monthly monitoring.

Most people who stop tolvaptan do so because of aquaresis burden — not liver effects. Discuss night-time dosing strategies with your nephrologist.

Monitoring requirements

Liver monitoring is mandatory. Do not skip these appointments.
  • Liver function tests (ALT, AST, bilirubin) monthly for the first 18 months
  • Every 6 months after 18 months
  • If ALT rises above 3× the upper limit of normal → stop tolvaptan immediately and contact your prescriber
  • eGFR and electrolytes checked regularly (frequency per your nephrologist)
  • Blood pressure monitoring — ongoing at home

Long-term safety data: PMID36191725

Living with tolvaptan — practical notes

  • Carry water everywhere. Your kidneys cannot conserve water while on this drug. Dehydration is a real risk in hot weather, exercise, or illness with vomiting/diarrhoea — stop the drug and contact your team.
  • Avoid grapefruit and grapefruit juice. It inhibits CYP3A4 and can raise tolvaptan levels dangerously.
  • Plan for bathroom access at work and in travel. This affects job and lifestyle decisions — discuss upfront.
  • Morning dosing of the higher dose allows aquaresis to peak during waking hours. Your prescriber will guide the split-dose schedule.
  • Start dates matter: do not start during a period of illness, planned surgery, or other major stress on your kidneys.

Questions to ask before starting

  • QDo I qualify by Mayo Class or PROPKD?
  • QWhat is my baseline eGFR and trend?
  • QWhere will I get my monthly liver tests?
  • QWhat do I do if I get a stomach bug and cannot keep fluids down?
  • QWill this interact with any of my current medications?
  • QWhat is the cost and is it covered by my insurance or public plan?

What tolvaptan is not

Not a cure. Tolvaptan slows the rate of cyst growth and eGFR decline. It does not halt progression permanently or reverse cysts already present. Patients still progress to ESRD, just more slowly on average.

Not for everyone with ADPKD. If your Mayo Class is 1A or 1B, the risk-benefit calculation usually does not favour tolvaptan. Starting it early without evidence of rapid progression adds side-effect burden without proven benefit.

Not something to evaluate from headlines. Both fear ("I heard it damages the liver") and over-optimism ("it stops ADPKD") misrepresent the evidence. Tolvaptan belongs in a shared decision-making conversation with a nephrologist who knows your case.